EP1123136A1 - Neuro-immune-endocrine regulating device and treatment - Google Patents
Neuro-immune-endocrine regulating device and treatmentInfo
- Publication number
- EP1123136A1 EP1123136A1 EP98952977A EP98952977A EP1123136A1 EP 1123136 A1 EP1123136 A1 EP 1123136A1 EP 98952977 A EP98952977 A EP 98952977A EP 98952977 A EP98952977 A EP 98952977A EP 1123136 A1 EP1123136 A1 EP 1123136A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- orbital
- axis
- photostimulating
- cerebral cortex
- roofs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0618—Psychological treatment
Definitions
- This invention which comprises a device and method of treatment, applies principles of photobiology to the field of neuro-immune-endocrinology.
- the invention is designed to photostimulate pigmented neurons in the orbital areas of the cerebral cortex with filtered light. It is known that there are direct afferent and efferent projections between the orbital areas of the cerebral cortex and the hypothalamus.
- the hypothalamus- pituitary-adrenal axis and the brain-bone marrow axis have a central role in neuro- immune-endocrine regulation.
- the device has optical and electronic components with (but not restricted to) the following specifications. All such technical specifications concerning the device provided throughout this document are for the purpose of illustration, not of limitation.
- the optical components comprise two lens-holders made of plastic or other light-weight material (of cylindrical or other form).
- Each holder is equipped with a quartz glass (diameter : about 9mm, thickness : 1,1mm), placed at the tip, a biconvex lens (minimum 50 dioptres, diameter : about 9mm, thickness : 3mm ; or of other specifications suitable for photostimulating the orbital areas of the cerebral cortex) placed at the appropriate focal distance inside.
- each biconvex lens In front of each biconvex lens is a filter with (or without) a diffuser (diameter : about 9mm, thickness : 1mm), transmitting wavelengths with peaks at 350-400nm and 750-800nm (or with other peaks suitable for photostimulating the orbital areas of the cerebral cortex).
- a low- powered (2.7V-4V) medical bulb (or light source of similar power) is positioned behind each biconvex lens near the base of each holder.
- the two holders are mounted in a rectangular plastic casing (approx. 132mm x 170mm) which contains a printed circuit, battery housing (for the battery model) and a pivot mechanism for positioning the holders at different sites of the orbital roofs.
- the input is 6V DC (battery model), 220V DC
- the device (mains model) and output is 0.5 - 3V DC (variable) ; 50 - 300 mA .
- the device is equipped with an output regulator, and a digital display showing voltage or mA.
- a hospital model of the device is planned which will include computerized circuits comprising craniometric, densitometric, and other programmable functions.
- the method of treatment consists of placing the tips of the lens-holders consecutively at three or more contiguous sites of each orbital roof for periods of 2 to 4 minutes per site. This treatment is administered twice weekly for a period of up to two months. According to the pathology and the condition of the patient, treatment may be repeated for similar periods as required. Patients are treated in a recumbent (or seated) position, with eyes closed. It must be emphasized that the treatment itself makes no use of the eyes ; in other words, no light is sent through retinal pathways.
- the orbital roof was selected as the point of entry for photostimulation, since it consists of a thin translucent layer of bone tissue.
- the weight of the hand-held model of the device should not exceed 500gr.
- the lens-holders can be made of various light-weight substances, non- conductive material such as hard plastic is recommended. - The tip of each holder must be smooth enough to avoid scratching or causing irritation to the roofs of the orbits. Although filters of 2mm thickness can be used, 1mm thickness is recommended to ensure efficient light transmittance.
- each filter facing the light source should have a diffuser.
- - Lenses of various specifications can be used. However, lenses should meet the following requirements : 50 dioptres (minimum) ; 100 dioptres (maximum) ; biconvex.
- AR coating is recommended for the lenses and quartz glasses.
- Treatment should be carried out in subdued lighting conditions (i.e. a low- powered, shaded non-halogen lamp should be used ; fluorescent tubes must be avoided).
- the duration of the treatment per orbital site should be no less than 2 minutes. However, periods of 3-4 minutes per site tend to be particularly effective in most cases.
- treatment should be given for an initial period of two months.
- this medical device can be produced at relatively low cost.
- the optical and electronic parts can be produced independently and are simple to assemble.
- an upgraded hospital model could be used in conjunction with brain-imaging devices, EEGs and other neurological equipment.
- the method of claim 1 wherein the treatment uses the orbital roof as the point of entry for photostimulating the orbital areas of the cerebral cortex. 3. The method of claims 1 or 2 wherein the treatment uses the tips of the lens- holders of the specified device consecutively at three or more contiguous sites of each orbital roof. 4. The method of claim 3 wherein the treatment is administered for periods of 2 to 4 minutes per site. 5. The method of claim 4 wherein the treatment is administered twice weekly for a period of 2 months and for further such periods as required. 6. The method of claim 1 wherein the treatment entails the use of filtered light peaking at 350-400nm and 750-800nm (or with other peaks suitable for photostimulating the orbital areas of the cerebral cortex). 7.
- the method of claims 1 or 6 wherein the treatment entails the use of low- powered medical bulbs (2.7V-4V) or other light source of similar power, with an intensity range of 50 - 300mA.
- the treatment is administered to patients in a recumbent (or seated) position, with eyes closed.
- essential hypertension can be treated through a modulation of the hypothalamus-pituitary-adrenal axis and/or of the brain-bone marrow axis, or of some other axis, by photostimulating the orbital areas of the cerebral cortex via the orbital roofs with the device specified.
- chronic pharyngitis can be treated through a modulation of the hypothalamus-pituitary-adrenal axis and/or of the brain-bone marrow axis, or of some other axis, by photostimulating the orbital areas of the cerebral cortex via the orbital roofs with the device specified.
- the method of claims 1 or 6 wherein immunodeficency arising from any cause whatsoever can be treated through a modulation of the hypothalamus-pituitary- adrenal axis and/or of the brain-bone marrow axis, or of some other axis, by photostimulating the orbital areas of the cerebral cortex via the orbital roofs with the device specified.
- the method of claims 1 or 6 wherein cancer can be treated through a modulation of the hypothalamus-pituitary-adrenal axis and/or of the brain-bone marrow axis, or of some other axis, by photostimulating the orbital areas of the cerebral cortex via the orbital roofs with the device specified.
- systemic lupus erythematosus can be treated through a modulation of the hypothalamus-pituitary-adrenal axis and/or of the brain-bone marrow axis, or of some other axis, by photostimulating the orbital areas of the cerebral cortex via the orbital roofs with the device specified.
- eczema can be treated through a modulation of the hypothalamus-pituitary-adrenal axis and/or of the brain-bone marrow axis, or of some other axis, by photostimulating the orbital areas of the cerebral cortex via the orbital roofs with the device specified.
- thyroid disease can be treated through a modulation of the hypothalamus-pituitary-adrenal axis and/or of the brain-bone marrow axis, or of some other axis, by photostimulating the orbital areas of the cerebral cortex via the orbital roofs with the device specified.
- viral syndromes can be treated through a modulation of the hypothalamus-pituitary-adrenal axis and/or of the brain-bone marrow axis, or of some other axis, by photostimulating the orbital areas of the cerebral cortex via the orbital roofs with the device specified.
- a device as described in claim 1 comprising (at least) two lens-holders, each with a quartz glass and a lens of 50 dioptres (minimum), both of about 9mm diameter and/or of such specifications as are required for photostimulating the orbital areas of the cerebral cortex.
- a device as described in claims 1 or 21 comprising filters of about 9mm diameter, with (or without) diffusers. 23.
- a device as described in claim 22 comprising filters transmitting wavelengths with peaks at 350-400 nm and 750-800nm or with any other peaks appropriate for photostimulating the orbital areas of the cerebral cortex.
- 24. A device as described in claim 21 using low-powered medical bulbs (2.7V- 4V) or other light sources of similar power and an intensity range of 50 to 300 mA.
- a device as described in claim 21 equipped with an output regulator, and a (digital) display showing voltage or mA.
- a device as described in claims 1 or 21 equipped with computerized circuits comprising craniometric, densitometric, and other programmable functions.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Disabilities (AREA)
- Hospice & Palliative Care (AREA)
- Social Psychology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB1998/001865 WO2000024465A1 (en) | 1998-10-23 | 1998-10-23 | Neuro-immune-endocrine regulating device and treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1123136A1 true EP1123136A1 (en) | 2001-08-16 |
Family
ID=11004782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98952977A Withdrawn EP1123136A1 (en) | 1998-10-23 | 1998-10-23 | Neuro-immune-endocrine regulating device and treatment |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1123136A1 (en) |
JP (1) | JP2002528192A (en) |
KR (1) | KR20010107926A (en) |
CN (1) | CN1327392A (en) |
AU (1) | AU1049499A (en) |
BR (1) | BR9816059A (en) |
CA (1) | CA2348792A1 (en) |
EA (1) | EA003414B1 (en) |
MX (1) | MXPA01004044A (en) |
WO (1) | WO2000024465A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2550993B1 (en) * | 2011-03-29 | 2014-12-10 | Valkee Oy | Devicefor altering dopamine Level |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4649151A (en) * | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
US4649935A (en) * | 1984-05-21 | 1987-03-17 | Symtonic Sa | Method of treating neurovegetative disorders and apparatus therefor |
CH676671A5 (en) * | 1989-07-03 | 1991-02-28 | Teclas Tecnologie Laser S A | |
DE69026960T2 (en) * | 1990-01-08 | 1996-09-05 | Health Research Inc | DIVE ARRANGEMENT WITH LENS AND OPTICAL FIBER |
RU2071795C1 (en) * | 1994-01-31 | 1997-01-20 | Акционерное общество "Научно-производственное акционерное предприятие Алтаймедприбор" | Apparatus for producing physiotherapeutic action on patient |
RU2074753C1 (en) * | 1994-06-09 | 1997-03-10 | Владимир Михайлович Дрюков | Device for physical therapy |
-
1998
- 1998-10-23 MX MXPA01004044A patent/MXPA01004044A/en unknown
- 1998-10-23 CA CA002348792A patent/CA2348792A1/en not_active Abandoned
- 1998-10-23 EA EA200100463A patent/EA003414B1/en not_active IP Right Cessation
- 1998-10-23 WO PCT/IB1998/001865 patent/WO2000024465A1/en not_active Application Discontinuation
- 1998-10-23 AU AU10494/99A patent/AU1049499A/en not_active Abandoned
- 1998-10-23 JP JP2000578066A patent/JP2002528192A/en active Pending
- 1998-10-23 BR BR9816059-1A patent/BR9816059A/en not_active IP Right Cessation
- 1998-10-23 EP EP98952977A patent/EP1123136A1/en not_active Withdrawn
- 1998-10-23 KR KR1020017005071A patent/KR20010107926A/en not_active Application Discontinuation
- 1998-10-23 CN CN98814367A patent/CN1327392A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO0024465A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000024465A1 (en) | 2000-05-04 |
BR9816059A (en) | 2001-07-10 |
AU1049499A (en) | 2000-05-15 |
MXPA01004044A (en) | 2003-03-10 |
CN1327392A (en) | 2001-12-19 |
JP2002528192A (en) | 2002-09-03 |
CA2348792A1 (en) | 2000-05-04 |
KR20010107926A (en) | 2001-12-07 |
EA200100463A1 (en) | 2001-10-22 |
EA003414B1 (en) | 2003-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9138595B2 (en) | Hand-held programmable ocular light therapy apparatus and methods | |
US6488698B1 (en) | Portable light unit for treatment of seasonal affective disorders | |
US20050159795A1 (en) | Light and ion therapy apparatus and method | |
US5919217A (en) | Portable phototherapy unit | |
US6187030B1 (en) | Photodynamic therapy method | |
US5683436A (en) | Treatment of rhinitis by biostimulative illumination | |
KR890001272B1 (en) | Inserting device for illuminating light using cure | |
TW200510030A (en) | Modularized light processing of body components | |
DE69319701D1 (en) | Ophthalmic lens matched to the pupil | |
EP1078604A3 (en) | Device for therapeutic electromagnetic treatment | |
DE112004001731T5 (en) | Phototherapy equipment for the treatment of hyperbilirubinemia | |
CA2625697A1 (en) | Method and apparatus for sublingual application of light to blood | |
CN1008600B (en) | Solar ray energy radiating device for use in medical treatment | |
EP1123136A1 (en) | Neuro-immune-endocrine regulating device and treatment | |
AU598223B2 (en) | A solar ray energy radiation device for use in medical treatment | |
CN214306659U (en) | Eye-protecting health-care negative ion desk lamp | |
JP2013153965A (en) | Portable ocular light therapy device | |
CN2907746Y (en) | Semiconductor LED therapeutic head for nose | |
RU128494U1 (en) | DEVICE FOR IMPACT ON HUMAN BIORITHMS | |
US20220152412A1 (en) | Sublingual ultra violet wand device | |
CN2261240Y (en) | Physiotherapeutic spectacles | |
RU2040286C1 (en) | Irradiating device | |
CN2088879U (en) | Multifunctional pocket ultra-violet therapy apparatus | |
CN2058602U (en) | Weak eyesight therapeutic apparatus using glimmer red light | |
Hattersley | Full spectrum light: Energy and health builder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010409 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040501 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1038321 Country of ref document: HK |